THC brain study aims to uncover why people react differently to cannabis

NCT ID NCT06758596

Not yet recruiting Knowledge-focused Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study will give 144 healthy young adults (ages 18-21) a single dose of THC (7.5 mg) or a placebo in a capsule, then use brain scans and behavioral tasks to measure how THC affects mood, reward processing, and learning. The goal is to understand why some people respond differently to cannabis, which could inform future research on substance use disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: THC (tetrahydrocannabinol) in a 7.5 mg oral capsule
What this could lead to: If successful, this study could help explain why some people react differently to cannabis, potentially guiding future personalized treatments for substance use disorders.
What could go wrong: This is a very early, small study (144 participants) focused on healthy young adults, so results may not apply to the general population. It is designed to gather knowledge, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS USE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANNABIS USE HEALTHY SUBSTANCE USE DISORDER (SUD)

Contacts and locations

Locations

University of Illinois at Chicago

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.